Therapy Detail

Therapy Name BAL101553
Therapy Description

BAL101553 is the prodrug of the microtubule inhibiting drug BAL27862, which may result in decreased growth and migration of tumor cells (PMID: 27540016).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
BAL101553 Antimicrotubule Agent 11 BAL101553 is the prodrug of the microtubule inhibiting drug BAL27862, which may result in decreased growth and migration of tumor cells (PMID: 27540016).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable BAL101553 Phase I Actionable In a Phase I trial, BAL101553 treatment resulted in stable disease in 37% (7/19) of patients with advanced solid tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2530-2530; NCT02490800). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT03250299 Phase I BAL101553 Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Active, not recruiting